Related Experiment Video
Updated: Mar 19, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Hepatic Phosphoglucomutase Activity as a Marker of Oxidative Stress Induced by Pro-oxidative Drugs
H Ashida1, K Kanazawa1, G Danno1
1a Department of Biofunctional Chemistry , Kobe University , Rokkodai-cho, Nada-ku, Kobe 657 , Japan.
Abstract:
A decrease in hepatic phosphoglucomutase activity was found after intraperitoneal doses to rats with pro-oxidative drugs; carbon tetrachloride, ethanol, paraquat, phenobarbital, thiopental, 3-methylcholanthrene, benzo[a]pyrene, Trp-P-1, benzene, and polychlorinated biphenyl. When the drugs were given at half of their LD50 values, except ethanol, hepatic phosphoglucomutase activities were decreased, and aldehydes which were detected by the thiobarbituric acid test were simultaneously accumulated 24 h after administration, in the liver. A significant correlation between phosphoglucomutase activity and the accumulations of aldehydes was obtained (r = - 0.536). No other changes in hepatic enzymes and metabolites were commonly observed. On the other hand, the low-molecular-weight aldehyde fraction in secondary products of linoleic acid decreased phosphoglucomutase activity in hepatocytes cultured with dexamethasone. It was concluded that aldehydes originating from endogenous lipid peroxidation decreased phosphoglucomutase activity in the liver, and the assay of hepatic phosphoglucomutase activity was useful as a marker of oxidative stress induced by pro-oxidative drugs.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Phase I Oxidative Reactions: Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drug Metabolism: Phase I Reactions

